Document is current
Any future updates will be listed below
-
Authors
Abraham, Jean E. https://orcid.org/0000-0003-0688-4807
O’Connor, Lenka Oplustil https://orcid.org/0000-0001-7580-1572
Grybowicz, Louise
Alba, Karen Pinilla https://orcid.org/0000-0002-2723-0805
Dayimu, Alimu
Demiris, Nikolaos
Harvey, Caron
Drewett, Lynsey M.
Lucey, Rebecca https://orcid.org/0000-0002-6226-447X
Fulton, Alexander
Roberts, Anne N.
Worley, Joanna R.
Chhabra, Ms Anita https://orcid.org/0000-0002-9899-8010
Qian, Wendi https://orcid.org/0000-0002-4238-3471
Brown, Jessica
Hardy, Richard
Vallier, Anne-Laure
Chan, Steve
Cidon, Maria Esther Una
Sherwin, Elizabeth
Chakrabarti, Amitabha
Sadler, Claire
Barnes, Jen
Persic, Mojca
Smith, Sarah
Raj, Sanjay
Borley, Annabel
Braybrooke, Jeremy P.
Staples, Emma
Scott, Lucy C.
Palmer, Cheryl A.
Moody, Margaret
Churn, Mark J.
Pilger, Domenic https://orcid.org/0000-0001-7339-0685
Zagnoli-Vieira, Guido
Wijnhoven, Paul W. G.
Mukesh, Mukesh B.
Roylance, Rebecca R. https://orcid.org/0000-0003-1453-6343
Schouten, Philip C.
Levitt, Nicola C.
McAdam, Karen
Armstrong, Anne C. https://orcid.org/0000-0002-0774-7006
Copson, Ellen R.
McMurtry, Emma
Galbraith, Susan
Tischkowitz, Marc https://orcid.org/0000-0002-7880-0628
Provenzano, Elena
O’Connor, Mark J. https://orcid.org/0000-0003-1823-625X
Earl, Helena M.
,
-
Funding
Funding for this research was provided by:
Cancer Research UK (CRUKE/14/048)
AstraZeneca (1994-A093777)
- License Information
-
More Information
Article History
Received: 25 October 2024
Accepted: 11 April 2025
First Online: 13 May 2025
Competing interests
: The funders of the research grants and honoraria had no role in the study design, data collection, analysis, interpretation, or writing of the report. The authors declare the existence of the following competing interests: J.E.A. reports honoraria, conference attendance, travel support, and a grant from AstraZeneca; and honoraria from Esai and Pfizer for lectures. L.O.O.C. reports employment and shares in AstraZeneca. J.B. reports employment and stock in AstraZeneca. C.S. reports former employment and stock in AstraZeneca. J. Ba reports former employment and stock in AstraZeneca. M.M. reports shares in AstraZeneca. D.P. reports employment and shares in AstraZeneca. G.Z.V. reports employment and shares in AstraZeneca. P.W. reports employment and shares in AstraZeneca. M.B.M. reports advisory board membership in Roche, Pfizer, MSD, Daiichi-Sankyo, Gilead, AstraZeneca, Novartis, Menarini group, Genomic Health (Precision Medicine) & Seagen; speaker honoraria from Roche, BMS, Seagen, Pfizer, Daiichi-Sankyo, AstraZeneca, Lilly, MSD, Genomic Health (Precision Medicine), Eisai & Novartis; and meeting expenses from Roche, Eli Lilly, Novartis and MSD. R.R.R. reports honoraria from Daiichi-Sankyo, AstraZeneca, Novartis, Pfizer; membership in advisory boards for Daiichi-Sankyo, Eli Lilly, Pfizer, AstraZeneca; and travel/conference attendance for BMS, Pfizer, Roche. PCS reports that their partner is employed by AstraZeneca. N.C.L. reports shares in AstraZeneca. A.C.A. reports research funding paid to the Institution from AstraZeneca; conference fees and travel expenses from Roche and Novartis; conference fees from M.S.D.; membership on Roche and AstraZeneca advisory boards; and a grant for an educational project from Gilead. ERC reports honoraria from AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche; membership in advisory boards for AstraZeneca, Eli Lilly, Pfizer, Menarini Stemline UK, Novartis; consultancy for Pfizer, conference fees/travel/accommodation from Roche, Novartis; an educational grant from Daiichi-Sankyo; and research funding and support from SECA, AstraZeneca. S.G. reports employment and stock in AstraZeneca. EP reports honoraria from Roche, Novartis, and AstraZeneca. M.J.O.C. reports employment and shares in AstraZeneca.
